Coloplast A/S - Annual Report 2025/26 & Remuneration Report 2025/26

Coloplast delivered 6% organic growth and 4% EBIT growth in constant currencies for FY 2025/26, with strong performance in Chronic Care and Interventional Urology. The company reached 20% market share in Ostomy Care in the US and achieved a 52% reduction in scope 1 and 2 emissions since 2018/19. For FY 2026/27, Coloplast expects 5-7% organic growth and an EBIT margin of around 25%, supported by a 'Funding the Journey' program to offset gross margin pressures from inflation and ramp-up costs.